Disparities in Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor Prescription and Dispensing in the Israeli Population—A Retrospective Cohort Study
Authors' conclusion
Disparities in drug prescription exist, even in a country with universal health coverage. Addressing these disparities requires improvements in health care systems, education, and alert systems to overcome barriers to evidence-based interventions.
Study context
- Population
- Adults with T2D eligible for SGLT2i treatment in Israel, 2017–2023
- Participants
- 32,742 eligible patients
- Outcome
- Time between initial eligibility and first SGLT2i prescription
Methodological detailsmultivariable analyses adjusting for death as a competing risk
- Multivariable analyses adjusting for death as a competing risk
Main finding
As reported in the abstract
SGLT2i prescription
Prescribed SGLT2i
53%
Observational data: associations, not effects.
Original publication
Disparities in Sodium–Glucose Cotransporter 2 (SGLT2) Inhibitor Prescription and Dispensing in the Israeli Population—A Retrospective Cohort Study. Diabetes Care. Published 20 February 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →